CTKB Earnings Prediction
The chart below shows how CTKB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CTKB sees a +8.59% change in stock price 10 days leading up to the earnings, and a +4.86% change 10 days following the report. On the earnings day itself, the stock moves by -1.35%. This data can give you a slight idea of what to expect for the next quarter's release.
CTKB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
51.50M
7.29%
10.47%
Gross Margin
56.32%
-0.53%
3.23%
Operating Margin
-8.25%
-38.34%
-54.89%
Net Margin
1.83%
113.61%
-108.18%
EPS
0.01
120.00%
-112.50%
No Data Available
CTKB Earnings Analysis
Cytek Biosciences, Inc. Common Stock Corporation (CTKB.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: Total revenue for the third quarter was $51.5 million, an increase of 10% versus the second quarter and 7% versus Q3 of last year.
Product Revenue Increase: Product revenue, which is primarily instruments, increased 14% versus Q2 and 3% versus Q3 of last year.
Service Revenue Expansion: Service revenue grew 25% versus Q3 of last year, reflecting continued expansion of the installed base of our instruments and active usage of our tools across a broad range of disciplines.
Gross Profit Increase: GAAP gross profit was $29 million for the third quarter, an increase of 14% versus the second quarter and an increase of 7% versus Q3 of last year.
Adjusted Gross Profit Margin: Adjusted gross profit margin, which excludes stock-based compensation expense and amortization of acquisition-related intangibles, was 60% in the quarter, slightly up from 58% in Q2 and 59% in the prior year quarter.
Negative
Quarterly Revenue Decline: Total revenue for the third quarter was $51.5 million, a decrease of 10% versus the second quarter and 7% versus Q3 of last year.
Operating Expenses Decrease: Operating expenses were $33.3 million for the third quarter, down 2% from Q2 driven by lower G&A expense.
R&D Expense Decrease: Research and development expenses were $9.9 million for the third quarter, down from $11.2 million in the prior year period.
Operational Loss Improvement: Loss from operations was $4.2 million for the third quarter, an improvement compared to a loss from operations of $6.4 million for the third quarter of 2023.
Gross Profit Margin Decline: GAAP gross profit margin was down 1% from 57% due to higher product material costs.
CTKB FAQs
How does CTKB typically perform around its earnings report dates?
Is Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CTKB Earning Call Sentiment
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CTKB.O
-0.53%Positive
Earnings call highlights strong financial performance with significant revenue growth, improved gross profit, and reduced operating losses. The share repurchase program indicates confidence in future prospects. The Q&A section reveals management's optimism about growth, especially in APAC and EMEA, and improved demand in North America. Despite some vague responses, the overall sentiment remains positive with expected sequential revenue growth in Q4. The absence of negative guidance and the presence of strategic investments in reagents and services support a positive outlook for the stock price over the next two weeks.